Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the “PIPE”) for gross proceeds of approximately $50 million, before deducting offering expenses. The financing was led by Perceptive Advisors, with participation by new and existing institutional investors, including Commodore Capital, Vestal Point Capital, Vivo Capital, and a large biotech dedicated investor.
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that, following a successful outcome from a recent FDA meeting, it plans to accelerate the development of ALTO-207 for people with treatment resistant depression (TRD). The $50 million private placement announced today supports expanded development of ALTO-207, and the Company expects to initiate a Phase 3 study by early 2027 following Phase 3 readiness work and alignment with the FDA on the planned study design.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Alto (ANRO) To Contact Him Directly To Discuss Their Options
FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia (CIAS). There are currently no approved treatments for CIAS, a core feature of schizophrenia that severely impacts daily functioning and quality of life for millions of patients.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
NEW YORK - September 19, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. (NYSE: ANRO) of a class action securities lawsuit.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Alto (ANRO) To Contact Him Directly To Discuss Their Options
NEW YORK - September 18, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. (NYSE: ANRO) of a class action securities lawsuit.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Alto To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Alto (ANRO) To Contact Him Directly To Discuss Their Options
NEW YORK - September 17, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. (NYSE: ANRO) of a class action securities lawsuit.
NEW YORK - September 16, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. (NYSE: ANRO) of a class action securities lawsuit.
